- Home
- AG vs PRAX Comparison
AG vs PRAX Comparison
Compare AG & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | PRAX |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AG | PRAX |
|---|---|---|
| Price | $20.81 | $315.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $20.08 | ★ $455.14 |
| AVG Volume (30 Days) | ★ 27.6M | 580.4K |
| Earning Date | 02-19-2026 | 02-27-2026 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $965,571,000.00 | $7,463,000.00 |
| Revenue This Year | $107.63 | N/A |
| Revenue Next Year | $18.81 | $15,003.90 |
| P/E Ratio | $159.28 | ★ N/A |
| Revenue Growth | 83.84 | ★ 364.98 |
| 52 Week Low | $5.09 | $26.70 |
| 52 Week High | $27.90 | $326.91 |
Technical Indicators
Market Signals| Indicator | AG | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.92 | 59.77 |
| Support Level | $24.42 | $304.08 |
| Resistance Level | $27.25 | $323.40 |
| Average True Range (ATR) | 1.77 | 18.66 |
| MACD | 0.00 | -1.46 |
| Stochastic Oscillator | 20.70 | 80.33 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.